目的 探討壯腰健腎丸聯(lián)合柳氮磺吡啶治療強直性脊柱炎的臨床療效。方法 選取2014年3月-2015年12月延安市人民醫(yī)院收治的強直性脊柱炎患者86例，隨機分為對照組和治療組，每組各43例。對照組口服柳氮磺吡啶腸溶片，第1周，2片/次，2次/d；第2周，3片/次，2次/d；第3周后，4片/次，2次/d。治療組在對照組基礎(chǔ)上口服壯腰健腎丸，1丸/次，3次/d。兩組患者均治療6個月。觀察兩組的臨床療效，比較兩組的臨床癥狀指標、血清學(xué)指標的變化情況。結(jié)果 治療后，對照組和治療組的總有效率分別為76.74%、93.02%，兩組比較差異有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組胸廓活動度和腰椎活動度明顯升高，而枕墻距、巴氏強直性脊柱炎疾病活動指數(shù)（BASDAI）和巴氏強直性脊柱炎功能指數(shù)（BASFI）明顯下降，同組治療前后比較差異有統(tǒng)計學(xué)意義（P<0.05）；且治療組這些觀察指標的改善程度明顯優(yōu)于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組C反應(yīng)蛋白（CRP）、血沉（ESR）、白細胞介素-33（IL-33）及瘦素均明顯降低，同組治療前后比較差異有統(tǒng)計學(xué)意義（P<0.05）；且治療組這些觀察指標的降低程度明顯優(yōu)于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 壯腰健腎丸聯(lián)合柳氮磺吡啶治療強直性脊柱炎具有較好的臨床療效，可明顯改善患者臨床癥狀，降低炎性反應(yīng)，具有一定的臨床推廣應(yīng)用價值。

Objective To investigate the clinical effect of Zhuangyao Jianshen Pills combined with sulfasalazine in treatment of ankylosing spondylitis. Methods Patients (86 cases) with ankylosing spondylitis in Yan'an People's Hospital from March 2014 to December 2015 were randomly divided into control and treatment groups, and each group had 43 cases. Patients in the control group were po administered with Sulfasalazine Tablets, the dose was 2 tablets/time, twice daily at the first week, the dose was 3 tablets/time, twice daily at the second week, 4 tablets/time, twice daily after the third week. Patients in the treatment group were po administered with Zhuangyao Jianshen pills on the basis of the control group, 1 pill/time, three times daily. After treatment, the clinical efficacies were evaluated, and the changes of clinical symptom indexes and serological indexes in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 76.74% and 93.02%, respectively, and there was difference between two groups (P<0.05). After treatment, thoracic activity and lumbar activity in two groups were significantly increased, but occiput to wall distance, BASDAI scores, and BASFI scores in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, CRP, ESR, IL-33, and leptin in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Zhuangyao Jianshen Pills combined with sulfasalazine has clinical curative effect in treatment of ankylosing spondylitis, and can significantly improve clinical symptoms, decrease inflammatory reaction, which has a certain clinical application value.